SCHEMBL6492295

SCHEMBL6492295

CS(=O)(=O)c1ccc(CNc2ccc3oc4ccccc4c3c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 6/20 0.45
LMNA P02545 6/20 0.44
HTT P42858 6/20 0.44
ALDH1A1 P00352 5/20 0.44
MAPT P10636 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
HPGD P15428 2/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 2/20 0.44
USP2 O75604 2/20 0.44
TP53 P04637 1/20 0.44
MAOB P27338 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPK1 P28482 1/20 0.43
MMP12 P39900 2/20 0.42
MMP13 P45452 2/20 0.42
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768203 0.89 GHSR (0.43) GHSRMAOBCA12CA9CA1
SCHEMBL6491807 0.86 GHSR (0.46) GHSRLMNANPSR1MAPK1CA12
SCHEMBL6770045 0.86 SMN1; SMN2 (0.47) GHSRSMN1; SMN2CA12CA9CA1
SCHEMBL6497769 0.86 CA1 (0.48) GHSRALDH1A1MAPTMEN1KMT2A
SCHEMBL6493319 0.83 HTT (0.53) LMNAHTTALDH1A1MAPTMEN1
SCHEMBL6482295 0.82 HPGD (0.54) LMNAHTTALDH1A1MAPTMEN1
SCHEMBL7246584 0.82 CYP1A2 (0.53) LMNAHTTALDH1A1MAPTMEN1
SCHEMBL6493823 0.80 EGFR (0.50) HTTALDH1A1MAPTMEN1KMT2A
SCHEMBL6483213 0.80 PTPRF (0.58) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL7245463 0.80 MAOB (0.47) LMNAHTTALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 GHSR 1398/4885LMNA 3647/4885HTT 4405/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 GHSR 1845/4885LMNA 4305/4885HTT 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.